---
document_datetime: 2024-08-29 11:25:11
document_pages: 22
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zaltrap-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: zaltrap-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 12.3965928
conversion_datetime: 2025-12-30 22:50:00.302234
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zaltrap

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0072               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 27/08/2024                          |                                             | PL                               |           |
| II/0069/G            | This was an application for a group of variations.                                               | 07/12/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an   |            |            |             |                                                                                                                                                                                                                                                                                      |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0071 | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 30/11/2023 | n/a        |             |                                                                                                                                                                                                                                                                                      |
| II/0070 | Update of section 4.6 of the SmPC in order to update information regarding the duration of contraceptive use after cessation of treatment. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 05/10/2023 | 25/01/2024 | SmPC and PL | Women of childbearing potential should be advised to avoid becoming pregnant while on ZALTRAP, and should be informed of the potential hazard to the foetus. Women of childbearing potential treated with ZALTRAP must use effective contraception during treatment and for 3 months |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |          | after the last dose of treatment.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------------|
| II/0067/G | This was an application for a group of variations. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the AS B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New | 15/12/2022 | 25/01/2024 | Annex II |                                     |

<div style=\"page-break-after: always\"></div>

|         | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting   |            |            |                        | material/intermediate   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------|
| T/0068  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 31/10/2022 | 21/11/2022 | SmPC, Labelling and PL |                         |
| IB/0065 | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/07/2022 | n/a        |                        |                         |

<div style=\"page-break-after: always\"></div>

| N/0066              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                 | 13/07/2022   | 21/11/2022   | PL   |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------|-----------------------------------|
| PSUSA/10019 /202108 | Periodic Safety Update EU Single assessment - aflibercept (oncological indication(s))                                                                                                                                                                                                                                                                                                                                                                                            | 10/03/2022   | n/a          |      | PRAC Recommendation - maintenance |
| IB/0064/G           | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation                                                                                                                                                                  | 14/12/2021   | n/a          |      |                                   |
| N/0063              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                 | 08/11/2021   | 21/11/2022   | PL   |                                   |
| IB/0061/G           | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 18/06/2021   | n/a          |      |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10019 /202008   | Periodic Safety Update EU Single assessment - aflibercept (oncological indication(s))                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/03/2021   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| IB/0060/G             | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other | 26/02/2021   | n/a   |                                     |
| II/0058/G             | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 14/01/2021   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

|           | Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB   |            |            |                       | A.4 -   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------|
| WS/1829   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                    | 12/11/2020 | 09/12/2021 | SmPC, Annex II and PL |         |
| II/0055/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for -replacement or addition of a site where                                                                                                                                 | 02/04/2020 | n/a        |                       | the AS  |

<div style=\"page-break-after: always\"></div>

|                     | batch control/testing takes place B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |            |            |                       |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------|
| IB/0056/G           | This was an application for a group of variations. B.I.a.z - Change in manufacture of the AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                              | 11/03/2020 | n/a        |                       |                                   |
| PSUSA/10019 /201908 | Periodic Safety Update EU Single assessment - aflibercept (oncological indication(s))                                                                                                                                                                                                                                                                                                                                                                                                           | 13/02/2020 | n/a        |                       | PRAC Recommendation - maintenance |
| IB/0054             | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                                                                                                         | 06/02/2020 | n/a        |                       |                                   |
| IAIN/0052           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                  | 30/10/2019 | 15/10/2020 | SmPC, Annex II and PL |                                   |
| II/0051             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission                                                                                                                                                                                                                                                                                                                                                                                         | 14/06/2019 | n/a        |                       |                                   |

<div style=\"page-break-after: always\"></div>

|                     | of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10019 /201808 | Periodic Safety Update EU Single assessment - aflibercept (oncological indication(s))                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 14/02/2019 | n/a | PRAC Recommendation - maintenance |
| IB/0049/G           | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting | 09/01/2019 | n/a |                                   |
| IB/0050             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 04/01/2019 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                    |            |     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IA/0047             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                  | 18/10/2018 | n/a |                                   |
| IA/0046             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                               | 04/10/2018 | n/a |                                   |
| IB/0045             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                            | 04/05/2018 | n/a |                                   |
| PSUSA/10019 /201708 | Periodic Safety Update EU Single assessment - aflibercept (oncological indication(s))                                                                                                                                             | 08/03/2018 | n/a | PRAC Recommendation - maintenance |
| II/0044             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                     | 01/02/2018 | n/a |                                   |
| IB/0043             | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) | 15/12/2017 | n/a |                                   |
| II/0040             | B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS -                                                                                                                              | 07/12/2017 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method                                                                                                                                                                                                                                                           |            |            |                       |                                                                                                                                                                                                                                                                       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0042/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 04/12/2017 | n/a        |                       |                                                                                                                                                                                                                                                                       |
| II/0038   | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                                                                                                                 | 28/09/2017 | n/a        |                       |                                                                                                                                                                                                                                                                       |
| IB/0039   | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                             | 25/09/2017 | n/a        |                       |                                                                                                                                                                                                                                                                       |
| R/0037    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                             | 20/07/2017 | 21/09/2017 | SmPC, Annex II and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Zaltrap in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0036/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or                                                                                                                                                                                                                                                                                                   | 25/04/2017 | n/a        |                       |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                   |            |            |                   | starting material/reagent/intermediate   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|------------------------------------------|
| IB/0033/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure replacement or addition) | 01/03/2017 | n/a        |                   | (including                               |
| II/0035   | Update the Product Information (SmPC, section 5.1 Pharmacodynamic properties) to reflect the results of the biomarker programme encompassing the EFC10262, EFC10668 and EFC11338 studies in order to fulfil the Annex II condition of Zaltrap, aflibercept 25 mg/ml, Concentrate for solution for infusion (EMEA/H/C/002532).                                                                                                                                                                                         | 23/02/2017 | 21/09/2017 | SmPC and Annex II |                                          |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                            |            |     |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| II/0034             | Submission of the final results of the Drug Utilisation Study monitoring the use of Zaltrap in cancer patients including potential off-label use and evaluating the potential for intravitreal use. This fulfils the post authorisation commitment MEA 03. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                     | 23/02/2017 | n/a |                                   |
| PSUSA/10019 /201608 | Periodic Safety Update EU Single assessment - aflibercept (oncological indication(s))                                                                                                                                                                                                                                                                                                                                                        | 09/02/2017 | n/a | PRAC Recommendation - maintenance |
| IB/0032             | B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products                                                                                                                                                                                                                                                                                                                    | 17/11/2016 | n/a |                                   |
| II/0025/G           | This was an application for a group of variations. B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits | 10/11/2016 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0030 | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 09/11/2016 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0026 | Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to add the adverse reactions cardiac failure and ejection fraction decreased and to recommend the discontinuation of Zaltrap in case these adverse reactions occur. This update reflects the results of a safety cumulative review. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 15/09/2016 | 24/10/2016 | SmPC and PL | Cardiac failure and ejection fraction decreased have been reported in patients treated with Zaltrap. Baseline and periodic evaluations of left ventricular function should be considered while the patient is receiving Zaltrap. Patients should be monitored for signs and symptoms of cardiac failure and ejection fraction decreased. Discontinue ZALTRAP in patients who experience cardiac failure and ejection fraction decreased. |
| IA/0029 | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 21/07/2016 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0028 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 24/06/2016 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IA/0027/G           | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished                                                                                                                                                    | 11/05/2016   | n/a        |             |                                                                                                                                                               |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10019 /201508 | Periodic Safety Update EU Single assessment - aflibercept (oncological indication(s))                                                                                                                                                                                                                                                                                     | 25/02/2016   | 28/04/2016 | SmPC and PL | Please refer to Zaltrap-PSUSA/00010019/201508 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IB/0023             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                              | 15/03/2016   | n/a        |             |                                                                                                                                                               |
| IB/0022             | B.I.c.3.z - Changes in the test procedure for the immediate packaging of AS - Other variation                                                                                                                                                                                                                                                                             | 05/02/2016   | n/a        |             |                                                                                                                                                               |
| IB/0021/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or | 21/12/2015   | n/a        |             |                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                     | changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |    |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| PSUSA/10019 /201502 | Periodic Safety Update EU Single assessment - aflibercept (oncological indication(s))                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/09/2015 | n/a        |    | PRAC Recommendation - maintenance |
| N/0019              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 06/08/2015 | 28/04/2016 | PL |                                   |
| IB/0017/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation | 16/06/2015 | n/a        |    |                                   |
| IB/0016/G           | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                | 26/02/2015 | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation   |            |     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0015/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                            | 23/02/2015 | n/a |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                 |            |            |      |                                                                                                                                                                  |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0014             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                    | 12/02/2015 | n/a        |      |                                                                                                                                                                  |
| PSUSA/10019 /201408 | Periodic Safety Update EU Single assessment - aflibercept (oncological indication(s))                                                                                                                                                                                                                                                                                                               | 12/02/2015 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                |
| IB/0013/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 29/01/2015 | n/a        |      |                                                                                                                                                                  |
| II/0005             | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                                                              | 18/12/2014 | n/a        |      |                                                                                                                                                                  |
| PSUV/0009           | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                              | 25/09/2014 | 19/11/2014 | SmPC | Please refer to Zaltrap-EMEA-H-C-2532-PSUV-0009 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation. |
| IB/0012/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a                                                                                                                                                                                                                                                                                             | 12/11/2014 | n/a        |      |                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                      |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0454   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 17/07/2014 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| PSUV/0008 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 06/03/2014 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0007   | Update of section 4.4 of the SmPC in order to amend the existing warnings on proteinuria in line with a proposed amendment to the CCDS. Moreover, a minor rewording of the recommendation regarding recurrent hypertension is introduced in section 4.2 of the SmPC and the warning on hypertension in section 4.4 of the SmPC is amended accordingly. In addition, the MAH took the opportunity to update Annex II in line with the QRD template version 9 and to update the details of the local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 19/12/2013 | 27/06/2014 | SmPC, Annex II and PL | Proteinuria occurring during aflibercept treatment should be monitored by urine dipstick analysis and/or urinary protein creatinine ratio (UPCR) for the development or worsening of proteinuria before each aflibercept administration. Patients with a dipstick of 2+ for protein or a UPCR >1 should undergo a 24 hour urine collection. In case of recurrent medically significant or severe hypertension despite optimal treatment, ZALTRAP should be suspended until the hypertension is controlled and the dose reduced to 2 mg/kg for subsequent cycles. Aflibercept should be permanently discontinued if hypertension cannot be adequately managed with appropriate anti hypertensive therapy or aflibercept dose reduction, or if hypertensive crisis or hypertensive encephalopathy occurs. |

<div style=\"page-break-after: always\"></div>

| IB/0006   | B.I.d.1.b.3 - Stability of AS - Change in the storage conditions - Change in storage conditions of the AS   | 05/11/2013   | n/a        |      |
|-----------|-------------------------------------------------------------------------------------------------------------|--------------|------------|------|
| N/0003    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)            | 25/09/2013   | 27/06/2014 | PL   |
| IAIN/0004 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation              | 31/07/2013   | n/a        |      |
| IA/0001   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                               | 21/06/2013   | 27/06/2014 | SmPC |